<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>3</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2009</Year>
        <Month>03</Month>
        <Day>15</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluation of response, tolerability and toxicity of new chemotherapeutic regimen in advanced Gastric Cancer</title>
    <FirstPage>7</FirstPage>
    <LastPage>10</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mohammad Ali</FirstName>
        <LastName>Mashhadi</LastName>
        <affiliation locale="en_US">Hematology- Oncology Department, Ali Ebne Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>10</Month>
        <Day>01</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background:This study testing the effectiveness ,toxicity and tolereability of new chemotherapeutic regimen (consist of Irinotecan 5-FU and Leucovorin) in locally advanced and metastatic Gastric Cancer.
Patients and Methods: Patients with locally advanced gstric cancer (atleast stage 3)or metastatic gastric cancer that no treated previously with chemotherapeutic agents entered onto this study. Treatment consist of 6-12 cycles (every 2 weeks) with Irinotecan(CPT-11)140mg/m2iv,Lecovorin100mg/m2iv ,followed by 5-FU 400mg/m2(in4hours)and then 5-FU 1200m2(ci in 48h),all cycles given every 2 weeks and repeated atleast for 6 cycles(6-12 cycles).
Results: Ten(10) patients were enrolled and eligible patients received&#xA0;&#xA0; this protocol therapy.The over all response rate was 60% and 10% complete response,and50% with partial response and 10% stable disease. Median survival was 13 months and median event free survival was 8 months.&#xA0;The major toxicity was Neutropenia (grade 4) in 3 cases(30%), that two cases died in neutropenic sepsis feature.Grade 4 anemia was observed in one case that needs to transfusion therapy. Other mild side effect and toxicity of this protocol therapy were: Grade 1 neutropenia(10%),mild thrombocytopenia(10%),mild diarrhea (40% )mild nausea and vomiting (60%)and lethargia and mucositis were not seen.
Conclusion: This protocol consist of Irinotecan iv bolous that followed with Leucovorin and 5-FU in 4h and then 5-FU in 48h ci is very active in patients with locally advanced and metastatic Gastric Cancer. Diarrhea and mucositis were less than other reports.&#xA0;Future trials in large series need to documented effectiveness and tolereability and toxicity of this new protocol.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/200</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/200/193</pdf_url>
  </Article>
</Articles>
